Enovid (nitric oxide nasal spray) / SaNOtize - LARVOL DELTA

Novel Nitric Oxide-Releasing Formulations Show Fungicidal Potential for Superficial Dermatophyte Infection. (PubMed, J Fungi (Basel)) - "The clinical NORS treatment reduced the clinical symptom severity score by 67% on average, with no significant safety findings. These findings, in addition to existing publications, support NO-releasing formulations as potential therapies that warrant further clinical investigation for superficial fungal infection."

Journal • Dermatology • Infectious Disease

Broad-Spectrum Virucidal Activity of Nitric Oxide Nasal Spray (NONS) Against SARS-CoV-2 Variants and Major Respiratory Viruses. (PubMed, Viruses) - "Influenza A and B viruses showed the fastest loss of infectivity, reaching detection limits within 10-15 s. RSV, hMPV, HPIV-3, and human rhinovirus 14 were similarly inactivated within 1-2 min. These findings demonstrate that the NONS exhibits rapid and broad-spectrum virucidal activity against diverse respiratory viruses and supports its potential role in pandemic preparedness but also seasonal use."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Efficacy and safety of a topical nitric oxide-releasing solution (NORS) as a noninvasive treatment for plantar warts (verrucae plantaris). (PubMed, J Dermatolog Treat) - P2 | "NORS demonstrated favorable safety and early clinical activity, warranting larger, longer-term efficacy trials. ClinicalTrials.gov Identifier NCT05877313."

Clinical • Journal • Dermatology • Immunology • Oncology • Pain

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection (clinicaltrials.gov) - P3 | N=1389 | Terminated | Sponsor: Sanotize Research and Development corp. | Active, not recruiting ➔ Terminated; Recruitment challenges, i.e., not able to meet sample size targeted; secondary to the changing landscape of COVID-19 infection pathology.

Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

NONS-RARS-01: Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis (clinicaltrials.gov) - P2 | N=162 | Active, not recruiting | Sponsor: Sanotize Research and Development corp. | Trial primary completion date: Aug 2024 ➔ Feb 2025

Trial primary completion date • Otorhinolaryngology • Respiratory Diseases • Sinusitis

NONS-RARS-01: Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis (clinicaltrials.gov) - P2 | N=162 | Active, not recruiting | Sponsor: Sanotize Research and Development corp. | Recruiting ➔ Active, not recruiting

Enrollment closed • Otorhinolaryngology • Respiratory Diseases • Sinusitis

NONS-RARS-01: Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis (clinicaltrials.gov) - P2 | N=186 | Recruiting | Sponsor: Sanotize Research and Development corp. | Trial completion date: Sep 2024 ➔ Feb 2025

Trial completion date • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) (clinicaltrials.gov) - P2 | N=20 | Completed | Sponsor: Sanotize Research and Development corp. | Recruiting ➔ Completed | N=30 ➔ 20

Enrollment change • Trial completion • Dermatology • Oncology

NONS-RARS-01: Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis (clinicaltrials.gov) - P2 | N=186 | Recruiting | Sponsor: Sanotize Research and Development corp.

New P2 trial • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Sanotize Research and Development corp. | Phase classification: P2a ➔ P2 | Trial completion date: Dec 2023 ➔ Mar 2024

Phase classification • Trial completion date • Dermatology • Oncology

Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) (clinicaltrials.gov) - P2a | N=30 | Recruiting | Sponsor: Sanotize Research and Development corp. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Oncology

Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers (clinicaltrials.gov) - P1/2 | N=40 | Completed | Sponsor: Sanotize Research and Development corp. | Recruiting ➔ Completed

Trial completion

Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) (clinicaltrials.gov) - P2a | N=30 | Not yet recruiting | Sponsor: Sanotize Research and Development corp.

New P2a trial • Dermatology • Oncology

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection (clinicaltrials.gov) - P3 | N=1389 | Active, not recruiting | Sponsor: Sanotize Research and Development corp. | Trial completion date: Jul 2023 ➔ Apr 2024 | Trial primary completion date: Jul 2023 ➔ Jan 2024

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection (clinicaltrials.gov) - P3 | N=1389 | Active, not recruiting | Sponsor: Sanotize Research and Development corp. | Recruiting ➔ Active, not recruiting | N=13000 ➔ 1389 | Trial completion date: Nov 2022 ➔ Jul 2023 | Trial primary completion date: Nov 2022 ➔ Jul 2023

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Sanotize Research and Development corp. | Trial completion date: Dec 2022 ➔ Mar 2023 | Trial primary completion date: Dec 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date

"sanOtize nitric oxide nasal spray? (Enovid, Fabispray, VirX)" (@MirthWormSlim)

SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomised trial. (PubMed, Lancet Reg Health Southeast Asia) - "Funding provided by Glenmark Pharmaceuticals Limited. Study medication provided by SaNOtize."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Sanotize Research and Development corp. | Trial completion date: May 2022 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection (clinicaltrials.gov) - P3 | N=13000 | Recruiting | Sponsor: Sanotize Research and Development corp. | Trial completion date: May 2022 ➔ Nov 2022 | Trial primary completion date: Mar 2022 ➔ Nov 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection (clinicaltrials.gov) - P3 | N=13000 | Recruiting | Sponsor: Sanotize Research and Development corp. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection (clinicaltrials.gov) - P3; N=13000; Not yet recruiting; Sponsor: Sanotize Research and Development corp.

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"Dr. Alvarez, why did inopulse fail for Covid, but @SanotizeD 's Enovid NO spray seems to work?" (@DoodyGiuliani11)

Novel Coronavirus Disease

"Much better sanotize enovid nitric oxide" (@emmartine)

Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection (clinicaltrials.gov) - P2; N=0; Withdrawn; Sponsor: Sanotize Research and Development corp.; N=50 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease